Zhenghao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenghao Liu has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Hung-Ying Kao
Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
12 shared publications - Sichun Yang
Case Comprehensive Cancer Center and Department of Nutrition, School of Medicine, Case Western Reserve University; Cleveland, OH 44106, USA
12 shared publications - Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
11 shared publications - Li-Sheng Geng
Beihang University
11 shared publications - Ruth A. Keri
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
11 shared publications - Chen Wu
Department of Biochemistry and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
10 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 2: MTO demonstrates enhanced growth inhibition in endocrine-resistant T47D cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 2: MTO demonstrates enhanced growth inhibition in endocrine-resistant T47D cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 4: Evaluation of combination treatment effects between MTO and established ER antagonists in MCF7 cells
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 4: Evaluation of combination treatment effects between MTO and established ER antagonists in MCF7 cells
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 6: Comparative pathway analysis reveals distinct transcriptional effects of MTO and fulvestrant
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 6: Comparative pathway analysis reveals distinct transcriptional effects of MTO and fulvestrant
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 3: Three-dimensional spheroid growth in MCF7 cells expressing wildtype and mutant ER
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 3: Three-dimensional spheroid growth in MCF7 cells expressing wildtype and mutant ER
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 7 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 7: Comparative transcriptional pathway analysis of MTO and fulvestrant treatments
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 7 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 7: Comparative transcriptional pathway analysis of MTO and fulvestrant treatments
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Table 1: Analysis of top computational docking candidates from the NIH Clinical Collection
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Table 1: Analysis of top computational docking candidates from the NIH Clinical Collection
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 1: MTO, unlike fulvestrant, maintains E2-mediated ER-SRC3 interaction
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 1: MTO, unlike fulvestrant, maintains E2-mediated ER-SRC3 interaction
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 5: ER protein levels in wild-type and Y537S ER orthotopic xenograft tumors
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Supplementary Fig. 5: ER protein levels in wild-type and Y537S ER orthotopic xenograft tumors
- Open Access
- 21 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
PNPLA3-I148M genetic variant rewires lipid metabolism to drive programmed cell death in human hepatocytes
Genetic variants in lipid metabolism influence the risk of developing metabolic dysfunction–associated steatotic liver disease (MASLD), cirrhosis, and end-stage liver disease (ESLD). The mechanisms by which these variants drive disease are poorly understood. Because of the PNPLA3-I148M variant’s strong correlation with all stages of the MASLD spectrum and the lack of tractable therapeutic targets, we sought to understand its impact on cellular function and liver metabolism. Primary human hepatocytes (HAHs) and induced pluripotent stem cell–derived (iPSC-derived) hepatocytes (iHeps) from healthy individuals possessing the PNPLA3-I148M mutation were characterized for changes in lipid metabolism, cellular stress, and survival. Using lipidomics, metabolomics, stable isotope tracing, and flux propensity analysis, we created a comprehensive metabolic profile of the changes associated with the PNPLA3-I148M variant. Functional analysis showed that the presence of the PNPLA3-I148M variant increased endoplasmic reticulum stress, mitochondrial dysfunction, and peroxisomal β-oxidation, ultimately leading to cell death via ferroptosis. Nutritional interventions, ferroptosis-specific inhibitors, and genetic approaches modulating GPX4 activity in PNPLA3-I148M HAHs and iHeps decreased programmed cell death. Our findings indicate that therapies targeting ferroptosis in patients carrying the PNPLA3-I148M variant could affect the development of MASLD and ESLD and highlight the utility of iPSC-based models for the study of genetic contributions to hepatic disorders.
- 21 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Open AccessPNPLA3-I148M genetic variant rewires lipid metabolism to drive programmed cell death in human hepatocytes
Genetic variants in lipid metabolism influence the risk of developing metabolic dysfunction–associated steatotic liver disease (MASLD), cirrhosis, and end-stage liver disease (ESLD). The mechanisms by which these variants drive disease are poorly understood. Because of the PNPLA3-I148M variant’s strong correlation with all stages of the MASLD spectrum and the lack of tractable therapeutic targets, we sought to understand its impact on cellular function and liver metabolism. Primary human hepatocytes (HAHs) and induced pluripotent stem cell–derived (iPSC-derived) hepatocytes (iHeps) from healthy individuals possessing the PNPLA3-I148M mutation were characterized for changes in lipid metabolism, cellular stress, and survival. Using lipidomics, metabolomics, stable isotope tracing, and flux propensity analysis, we created a comprehensive metabolic profile of the changes associated with the PNPLA3-I148M variant. Functional analysis showed that the presence of the PNPLA3-I148M variant increased endoplasmic reticulum stress, mitochondrial dysfunction, and peroxisomal β-oxidation, ultimately leading to cell death via ferroptosis. Nutritional interventions, ferroptosis-specific inhibitors, and genetic approaches modulating GPX4 activity in PNPLA3-I148M HAHs and iHeps decreased programmed cell death. Our findings indicate that therapies targeting ferroptosis in patients carrying the PNPLA3-I148M variant could affect the development of MASLD and ESLD and highlight the utility of iPSC-based models for the study of genetic contributions to hepatic disorders.